Dr. Karen A. Holbrook, president of Ohio State University, joined Techne’s board in February. In February, BD Biosciences and Roche announced a collaboration to jointly identify and develop intracellular phosphorylation site antibodies. The companies will develop and validate the antibodies using BD Phosflow technology, and Roche will receive pre-launch access to the antibodies and a period of exclusive commercial access. In January, Millipore announced the formation of a Diagnostics strategic business unit to develop, market and sell materials to diagnostic manufacturers. Ryogen licensed the patent for the Aminopeptidase P gene to Invitrogen. Tocris Bioscience completed a $40 million management buyout in January. Tony Kenny of Momentum Corporate Finance joined the Board as chairman. Invitrogen entered into a strategic comarketing and development agreement with cell therapy service provider Progenitor Cell Therapy, which is initially focused on the application of its media and cell separation technologies for cell product-based applications. Invitrogen will offer SciQuest supplier management and procurement automation software solutions, allowing the purchase of products from different vendors with a single purchase order. In March, Per Peterson, MD, PhD, joined Invitrogen’s board. He recently retired as chairman of Research & Development for Johnson & Johnson. Gregg Fergus, formerly senior vice president of Sales and Global Operations for Affymetrix, joined Caden Biosciences as senior vice president of Corporate Development. In February, service provider Commonwealth Biotechnologies acquired Mimotopes, a provider of research-grade peptide products and applications for the drug discovery industry. AbD Serotec, a division of MorphoSys, signed an agreement to use Thermo Scientific’s DyLight fluorescent dyes in combination with its research antibodies to supply fluorescence reagents to be sold through its catalogue. Under a exclusive license and supply agreement, Dendritic Nanotechnologies, a Starpharma subsidiary, will supply EMD Biosciences with PrioFect transfection reagents based on Priostar dendrimers for DNA and siRNA transfection research. ITI Life Sciences licensed its fluorescence lifetime assay assets to Almac Sciences and Edinburgh Instruments. LabLogic Systems acquired Permandec, a UK-baseddistributor of scintillation cocktails. Parag Saxena resigned from Transgenomic’s board in March. Alnylam granted Bio-Rad Laboratories a license to provide RNAi research products under the Kreutzer-Limmer patent family.